Study Phase 3

Double-Blind, Placebo-Controlled Study to Assess the Effect of Early Intervention and/or Treatment With Epoetin Alfa on Anemia in Cancer Patients Receiving non-Platinum-Containing Chemotherapy

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Blood-Forming OrgansProduct ClassAntianemic PreparationsPharmacological SubgroupOther Antianemic PreparationsChemical SubgroupOther Antianemic PreparationsCondition StudiedAnemia, Neoplasms
Sponsor Protocol NumberCR005917 (EPO-INT-10)Enrollment375Data PartnerJohnson & Johnson% Female68%Mean/Median Age (Years)58.5% White96%

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.